Cargando…

Cancer Vaccine by Fusions of Dendritic and Cancer Cells

Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells repr...

Descripción completa

Detalles Bibliográficos
Autores principales: Koido, Shigeo, Hara, Eiichi, Homma, Sadamu, Namiki, Yoshihisa, Ohkusa, Toshifumi, Gong, Jianlin, Tajiri, Hisao
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825547/
https://www.ncbi.nlm.nih.gov/pubmed/20182533
http://dx.doi.org/10.1155/2009/657369
_version_ 1782177822489444352
author Koido, Shigeo
Hara, Eiichi
Homma, Sadamu
Namiki, Yoshihisa
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
author_facet Koido, Shigeo
Hara, Eiichi
Homma, Sadamu
Namiki, Yoshihisa
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
author_sort Koido, Shigeo
collection PubMed
description Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination.
format Text
id pubmed-2825547
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28255472010-02-24 Cancer Vaccine by Fusions of Dendritic and Cancer Cells Koido, Shigeo Hara, Eiichi Homma, Sadamu Namiki, Yoshihisa Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Clin Dev Immunol Review Article Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination. Hindawi Publishing Corporation 2009 2010-02-18 /pmc/articles/PMC2825547/ /pubmed/20182533 http://dx.doi.org/10.1155/2009/657369 Text en Copyright © 2009 Shigeo Koido et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Koido, Shigeo
Hara, Eiichi
Homma, Sadamu
Namiki, Yoshihisa
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
Cancer Vaccine by Fusions of Dendritic and Cancer Cells
title Cancer Vaccine by Fusions of Dendritic and Cancer Cells
title_full Cancer Vaccine by Fusions of Dendritic and Cancer Cells
title_fullStr Cancer Vaccine by Fusions of Dendritic and Cancer Cells
title_full_unstemmed Cancer Vaccine by Fusions of Dendritic and Cancer Cells
title_short Cancer Vaccine by Fusions of Dendritic and Cancer Cells
title_sort cancer vaccine by fusions of dendritic and cancer cells
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825547/
https://www.ncbi.nlm.nih.gov/pubmed/20182533
http://dx.doi.org/10.1155/2009/657369
work_keys_str_mv AT koidoshigeo cancervaccinebyfusionsofdendriticandcancercells
AT haraeiichi cancervaccinebyfusionsofdendriticandcancercells
AT hommasadamu cancervaccinebyfusionsofdendriticandcancercells
AT namikiyoshihisa cancervaccinebyfusionsofdendriticandcancercells
AT ohkusatoshifumi cancervaccinebyfusionsofdendriticandcancercells
AT gongjianlin cancervaccinebyfusionsofdendriticandcancercells
AT tajirihisao cancervaccinebyfusionsofdendriticandcancercells